April 06, 2015
Wellesley, Mass., April 06, 2015 –BCC Research (www.bccresearch.com) reveals in its new report on “silent” cancers that while oncology spending remains concentrated among the United States (U.S.) and the five largest European countries, the rising prevalence of cancer and greater patient access to treatments in emerging nations has propelled oncology to the fifth-largest therapy area in those markets.
According to experts, the number of global cancer cases is projected to rise by 75% in 2030, as the Western way of life, which sadly has been linked to cancer, is being adopted by many across the world. Cancers that are caused by infections, such as cervical cancer and some liver and stomach cancers, are currently under control and have decreasing incidence rates. However, experts feel that cancers of the lung, colon, and breast are rising in number.
Among the total spectrum of malignant diseases there is a group of cancers, which, although affecting smaller patient populations than the “big four,” are more devastating. These are the “silent cancers” which give little indication of their growth until an advanced stage, at which time prospects of successful treatment are much reduced and the prognosis is poor. These comprise of cervical cancer, ovarian cancer, brain cancer, oropharyngeal cancer, esophageal cancer, liver cancer, pancreatic cancer, and kidney cancer.
“Targeted therapies have dramatically increased their share of global oncology sales, from 11% a decade ago to 46% last year,” says BCC Research analyst Paul Evers. “Payers have intensified their scrutiny of the value of these medicines relative to their incremental benefits over existing treatments. At the same time, the average cost per month for a branded oncology drug in the U.S. is now approximately $10,000, up from an average of $5,000 a decade ago.”
Concentrated or single-payer health systems, and those utilizing health technology assessments to evaluate the value of treatments, tend to pay less than U.S. prices for medicines. The pricing discount mechanisms used in major European markets typically drive net prices down by approximately 20% to 40% compared with U.S. list prices.
Therapeutics for 'Silent' Cancers provides detailed market, technology, and industry analyses to help readers quantify and qualify the market for eight subtypes of cancer. Important trends are identified and sales forecasts by product categories and major country markets are provided through 2019.
Editors and reporters who wish to speak with the analyst should contact Steven Cumming at email@example.com.
Therapeutics for 'Silent' Cancers( PHM169A )
Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email firstname.lastname@example.org or visit www.bccresearch.com/media to request access to our library of market research.